Glaucoma: An Open-Window to Neurodegeneration and Neuroprotection

EPIDEMIOLOGY AND CLINICAL ASSESSMENT OF THE DISEASE<br>1. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects<br> C. Cedrone, R. Mancino, A. Cerulli, M. Cesareo and C. Nucci (Italy)<br>2. Predictive models to estimate the risk of glaucoma development and progression<br> F.A. Medeiros and R.N. Weinreb (USA)<br>3. Intraocular pressure and central corneal thickness<br> G. Manni, F. Oddone, V. Parisi, A. Tosto and M. Centofanti (Italy)<br>4. Angle-closure: risk factors, diagnosis and treatment <br> N. Amerasinghe and T. Aung (Singapore) <br>5. Early diagnosis in glaucoma<br> D.F. Garway-Heath (UK, Italy)<br>6. Monitoring glaucoma progression<br> P. Brusini (Italy) <br>ANATOMICAL AND FUNCTIONAL MONITORING<br>7. Standard automated perimetry and algorithms for monitoring glaucoma progressions<br> G.L. Scuderi, M. Cesareo, A. Perdicchi and S.M. Recupero (Italy) <br>8. Short-wavelength automated perimetry and frequency-doubling technology perimetry in glaucoma<br> P. Fogagnolo, L. Rossetti, S. Ranno, A. Ferreras and N. Orzalesi (Italy, Spain) <br>9. Scanning laser polarimetry and confocal scanning laser ophthalmoscopy: technical notes on their use in glaucoma<br> F. Ferreri, P. Aragona and G. Ferreri (Italy) <br>10. The role of OCT in glaucoma management (Italy) <br>11. Functional laser Doppler flowmetry of the optic nerve: physiological aspects and clinical applications<br> C.E. Riva and B. Falsini (Italy) <br>12. Advances in neuroimaging of the visual pathways and their use in glaucoma<br> F.G. Garaci, V. Cozzolino, C. Nucci, F. Gaudiello, A. Ludovici, T. Lupattelli, R. Floris and G. Simonetti (Italy) <br>CURRENT THERAPY<br>13. Primary open angle glaucoma: an overview on medical therapy<br> M. Vetrugno, F. Cantatore, G. Ruggeri, P. Ferreri, A. Montepara, A. Quinto and C. Sborgia (Italy) <br>14. The treatment of normal tension glaucoma<br> P.V. Desai and J. Caprioli (USA) <br>15. The management of exfoliative glaucoma<br> R. Rich (USA) <br>16. Laser therapies for glaucoma: new frontiers<br> G.L. Scuderi and N. Pasquale (Italy) <br>17. Modulation of wound healing during and after glaucoma surgery<br> S. Georgoulas, A. Dahlmann-Noor, S. Brocchini and P.-T. Khaw (UK) <br>18. Surgical alternative to trabeculectomy<br> R.G. Carassa (Italy) <br>19. Modern aqueous shunt implantation ¡§C future challenges<br> K. Barton and D.K. Heuer (London, UK and Milwaukee, USA) <br>EXPERIMENTAL APPROACHES TO MODEL DISEASE<br>20. Model systems for experimental studies: retinal ganglion cells in culture<br> E. Goodyear, and L.A. Levin (Canada) <br>21. Rat models for glaucoma research<br> J.C. Morrison, E. Johnson and W.O. Cepurna (USA) <br>22. Mouse genetic models: an ideal system for understanding glaucomatous neurodegeneration and neuroprotection<br> R. Howell, R.T. Libby and S.W.M. John (USA) <br>23. Clinical trials in neuroprotection<br> S.M. Whitcup (USA) <br>NEUROPROTECTION: NEW VISTAS IN PATHOPHYSIOLOGY<br>24. Pathogenesis of ganglion cells in glaucoma and neuroprotection: Focus on ganglion cell axonal mitochondria <br> N.N. Osborne (UK) <br>25. Astrocytes in glaucomatous optic neuropathy<br> M.R. Hernandez, H. Miao and T. Lukas (USA) <br>26. Glaucoma as a neuropathy amenable to neuroprotection and immune manipulation<br> M. Schwartz and A. London (Israel) <br>27. Oxidative stress and glaucoma. Injury in the anterior segment of the eye<br> S.C. Sacca and A. Izzotti (Italy) <br>28. TNF-alpha signalling in glaucomatous neurodegeneration<br> G. Tezel (USA) <br>29. Involvement of the Bcl2 gene family in the signalling and control of retinal ganglion cell death <br> R.W. Nickells, S.J. Semaan and C.L. Schlamp (USA) <br>30. Assessment of neuroprotection in the retina with DARC<br> L.Guo and M.F. Cordeiro (UK) <br>31. Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection<br> C. Nucci, M. Bari, A. Spano, M.T. Corasaniti,, G. Bagetta, M. Maccarrone and L.A. Morrone (Italy) <br>32. Glaucoma of the brain: a disease model for the study of transsynaptic neural degeneration<br> Y. Yücel and N. Gupta (USA) <br>33. Changes of central visual receptive fields in experimental glaucoma<br> S.C. Sharma (USA) <br>NEUROPROTECTION: EVIDENCE FOR FUTURE STRATEGIES<br>34. Targeting excitotoxic/free radical signalling pathways for therapeutic intervention in glaucoma<br> M. Seki and S.A. Lipton (USA) <br>35. Stem cells for neuroprotection in glaucoma<br>N.D. Bull, T.V. Johnson and K.R. Martin (UK) <br>36. The relationship between neurotrophic factors and CaMKII in the death and survival of retinal ganglion cells<br> N.G.F. Cooper, A. Laabich, W. Fan and X. Wang (USA) <br>37. Evidence of the neuroprotective role of Citicoline in glaucoma patients<br> V. Parisi, G. Coppola, M. Centofanti, F. Oddone, A.-M. Angrisani, L. Ziccardi, B. Ricci, L. Quaranta and G. Manni (Italy) <br>38. Neuroprotection: VEGF, IL-6 and cluster in the dark side of the moon<br> S. Pucci, P. Mazzarelli, F. Missiroli, F. Regine and F. Ricci (Italy) <br>39. Rational basis for the development of coenzyme Q10 as a neurotherapeutic agent for retinal protection<br> R. Russo, F. Cavaliere, L. Rombol¡§¡è, M. Gliozzi, A. Cerulli, C. Nucci, E. Fazzi, G. Bagetta, M.T. Corasaniti and L.A. Morrone (Italy) <br>40. 17 beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat<br> R. Russo, F. Cavaliere F., C. Watanabe, C. Nucci, G. Bagetta, M. T. Corasaniti, S. Sakurada and L. A. Morrone (Italy, Japan)